Ligand Pharma (LGND) Tops Q1 EPS by 11c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.33, $0.11 better than the analyst estimate of $1.22. Revenue for the quarter came in at $45.33 million versus the consensus estimate of $37.92 million.
GUIDANCE:
Ligand Pharma sees FY2025 EPS of $6.00-$6.25, versus the consensus of $6.11. Ligand Pharma sees FY2025 revenue of $180-200 million, versus the consensus of $191.3 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- ONE Gas (OGS) Tops Q3 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Sinda Ltd. (SIND) Reports Q3 Loss of $0.10
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
